Navigating the regulatory path of CRISPR-based therapeutics

Unlocking the full potential of CRISPR-based therapeutics calls for technical innovation, strict compliance with regulatory standards, and ongoing collaboration with regulatory bodies. While developing treatments for genetic and rare diseases can be time-consuming, engaging with the FDA's Expedited Programs can streamline the process. Recent signals from the FDA's Center for Biologics Evaluation and Research suggest a growing preference for Accelerated Approval for gene therapies, underscoring the agency's commitment to expediting access to crucial treatments for rare conditions. GenScript offers invaluable guidance for navigating the intricate regulatory landscape of cell and gene therapies, empowering stakeholders to chart a course for success.